{
    "root": "dabdb746-a0fb-4208-ab3c-32e638396713",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Heparin Sodium",
    "value": "20250318",
    "ingredients": [
        {
            "name": "heparin sodium",
            "code": "ZZ45AB24CA",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_230519"
        },
        {
            "name": "sodium chloride",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "hydrochloric acid",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "sodium hydroxide",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "water",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "heparin sodium injection indicated : prophylaxis treatment venous thrombosis pulmonary embolism ; prevention postoperative deep venous thrombosis pulmonary embolism patients undergoing major abdominothoracic surgery , reasons , risk developing thromboembolic disease ; atrial fibrillation embolization ; treatment acute chronic consumptive coagulopathies ( disseminated intravascular coagulation ) ; prevention clotting arterial cardiac surgery ; prophylaxis treatment peripheral arterial embolism . anticoagulant blood transfusions , extracorporeal circulation , dialysis procedures .",
        "doid_entities": [
            {
                "text": "thrombosis (DOID:0060903)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060903"
            },
            {
                "text": "pulmonary embolism (DOID:9477)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9477"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            },
            {
                "text": "disseminated intravascular coagulation (DOID:11247)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11247"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended adult dosages : therapeutic anticoagulant effect full-dose heparin \u2020 ( 2.3 ) \u2020 based 150 lb ( 68 kg ) patient . adjust dose based laboratory monitoring . deep subcutaneous ( intrafat ) injection different site injection initial dose 5,000 units intravenous injection followed 10,000 20,000 units concentrated solution , subcutaneously every 8 hours every 12 hours 8,000 10,000 units concentrated solution 15,000 20,000 units concentrated solution intermittent intravenous injection initial dose 10,000 units , either undiluted 50 100 ml 0.9 % sodium chloride injection , usp every 4 6 hours 5,000 10,000 units , either undiluted 50 100 ml 0.9 % sodium chloride injection , usp intravenous infusion initial dose 5,000 units intravenous injection continuous 20,000 40,000 units/24 hours 1,000 ml 0.9 % sodium chloride injection , usp ( compatible solution ) infusion",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "heparin sodium injection , usp ( porcine ) , preservative free , available follows : ndc heparin sodium injection , usp ( 1,000 usp units per ml ) package factor 71288-400-03 2,000 usp units per 2 ml single-dose vial 25 vials per carton solution clear seal intact . solution discolored contains precipitate . sterile , nonpyrogenic , preservative-free.the container closure made natural rubber latex . discard unused portion .",
    "adverseReactions": "heparin sodium injection contraindicated patients following conditions : history heparin-induced thrombocytopenia heparin-induced thrombocytopenia thrombosis [ ( 5.3 ) ] ; known hypersensitivity heparin pork products ( e.g . , anaphylactoid ) [ ( 6.1 ) ] ; suitable blood coagulation tests , e.g . , whole blood clotting time , partial thromboplastin time , etc . , performed appropriate intervals ( contraindication refers full-dose heparin ; usually need monitor coagulation parameters patients receiving low-dose heparin ) ; uncontrolled active bleeding state [ ( 5.4 ) ] , except due disseminated intravascular coagulation .",
    "indications_original": "Heparin Sodium Injection is indicated for:\n\n                  \n                     Prophylaxis and treatment of venous thrombosis and pulmonary embolism;\n\n                     Prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease;\n\n                     Atrial fibrillation with embolization;\n\n                     Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation);\n\n                     Prevention of clotting in arterial and cardiac surgery;\n\n                     Prophylaxis and treatment of peripheral arterial embolism.\n\n                     Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures.",
    "contraindications_original": "Recommended Adult Dosages: Therapeutic Anticoagulant Effect with Full-Dose Heparin \u2020 ( 2.3 ) \u2020 Based on 150 lb (68 kg) patient. Adjust dose based on laboratory monitoring. Deep Subcutaneous (Intrafat) Injection Use a different site for each injection Initial Dose 5,000 units by intravenous injection followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously Every 8 hours or Every 12 hours 8,000 to 10,000 units of a concentrated solution 15,000 to 20,000 units of a concentrated solution Intermittent Intravenous Injection Initial Dose 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Every 4 to 6 hours 5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP Intravenous Infusion Initial Dose 5,000 units by intravenous injection Continuous 20,000 to 40,000 units/24 hours in 1,000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion",
    "warningsAndPrecautions_original": "Heparin Sodium Injection, USP (porcine), preservative free, is available as follows:\n\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              NDC\n                           \n                           \n                              Heparin Sodium Injection, USP (1,000 USP units per mL)\n                           \n                           \n                              Package Factor\n                           \n                        \n                        \n                           71288-400-03\n\n                           2,000 USP units per 2 mL Single-Dose Vial\n\n                           25 vials per carton\n\n                        \n                     \n                  \n                  Use only if solution is clear and seal intact. Do not use if solution is discolored or contains a precipitate.\n\n                  \n                     Sterile, Nonpyrogenic, Preservative-free.The container closure is not made with natural rubber latex.\n                  \n                  Discard unused portion.",
    "adverseReactions_original": "The use of heparin sodium injection is contraindicated in patients with the following conditions:\n\n                  \n                     History of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see Warnings and Precautions (5.3)];\n\n                     Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see Adverse Reactions (6.1)];\n                     \n                     In whom suitable blood coagulation tests, e.g., the whole blood clotting time, partial thromboplastin time, etc., cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin);\n\n                     An uncontrolled active bleeding state [see Warnings and Precautions (5.4)], except when this is due to disseminated intravascular coagulation.",
    "drug": [
        {
            "name": "Heparin Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_230519"
        }
    ]
}